相似文献
1
The validity of circulating microRNAs in oncology: five years of challenges and contradictions.
Mol Oncol. 2014 Jun;8(4):819-29. doi: 10.1016/j.molonc.2014.02.009. Epub 2014 Mar 6.
2
Circulating microRNAs: potential biomarkers for common malignancies.
Biomark Med. 2015;9(2):131-51. doi: 10.2217/bmm.14.102.
3
Current State of Circulating MicroRNAs as Cancer Biomarkers.
Clin Chem. 2015 Sep;61(9):1138-55. doi: 10.1373/clinchem.2015.241190. Epub 2015 Aug 3.
4
Circulating miRNAs as Biomarker in Cancer.
Recent Results Cancer Res. 2020;215:277-298. doi: 10.1007/978-3-030-26439-0_15.
5
Circulating miRNAs in cancer: from detection to therapy.
J Hematol Oncol. 2014 Dec 5;7:86. doi: 10.1186/s13045-014-0086-0.
6
Circulating miRNA and cancer diagnosis.
Sci China C Life Sci. 2009 Dec;52(12):1117-22. doi: 10.1007/s11427-009-0158-5. Epub 2009 Dec 17.
7
Micromarkers 2.0: an update on the role of microRNAs in cancer diagnosis and prognosis.
Expert Rev Mol Diagn. 2015;15(10):1369-81. doi: 10.1586/14737159.2015.1081058. Epub 2015 Sep 4.
8
Measurements Methods for the Development of MicroRNA-Based Tests for Cancer Diagnosis.
Int J Mol Sci. 2021 Jan 25;22(3):1176. doi: 10.3390/ijms22031176.
9
Profiling cell-free and circulating miRNA: a clinical diagnostic tool for different cancers.
Tumour Biol. 2016 May;37(5):5705-14. doi: 10.1007/s13277-016-4907-3. Epub 2016 Jan 29.
10
MicroRNAs as potential biomarkers in human solid tumors.
Cancer Lett. 2013 Feb 28;329(2):125-36. doi: 10.1016/j.canlet.2012.11.001. Epub 2012 Nov 27.
引用本文的文献
1
Role of Cancer Associated Fibroblast (CAF) derived miRNAs on head and neck malignancies microenvironment: a systematic review.
BMC Cancer. 2025 Apr 1;25(1):582. doi: 10.1186/s12885-025-13965-9.
2
Liquid biopsies in cancer.
Mol Biomed. 2025 Mar 20;6(1):18. doi: 10.1186/s43556-025-00257-8.
3
Integrated triple signal amplification strategy for ultrasensitive electrochemical detection of gastric cancer-related microRNA utilizing MoS-based nanozyme, hybridization chain reaction, and horseradish peroxidase.
J Nanobiotechnology. 2024 Oct 1;22(1):596. doi: 10.1186/s12951-024-02848-z.
4
Extracellular circulating miRNAs as potential non-invasive biomarkers in non-small cell lung cancer patients.
Front Oncol. 2023 Jul 21;13:1209299. doi: 10.3389/fonc.2023.1209299. eCollection 2023.
5
Critical Considerations for Investigating MicroRNAs during Tumorigenesis: A Case Study in Conceptual and Contextual Nuances of miR-211-5p in Melanoma.
Epigenomes. 2023 Apr 26;7(2):9. doi: 10.3390/epigenomes7020009.
6
MicroRNAs: Small Molecules with Significant Functions, Particularly in the Context of Viral Hepatitis B and C Infection.
Medicina (Kaunas). 2023 Jan 15;59(1):173. doi: 10.3390/medicina59010173.
7
Establishment of preanalytical conditions for microRNA profile analysis of clinical plasma samples.
PLoS One. 2022 Dec 14;17(12):e0278927. doi: 10.1371/journal.pone.0278927. eCollection 2022.
8
Urinary miRNAs as a Diagnostic Tool for Bladder Cancer: A Systematic Review.
Biomedicines. 2022 Oct 31;10(11):2766. doi: 10.3390/biomedicines10112766.
9
Dancing in local space: rolling hoop orbital amplification combined with local cascade nanozyme catalytic system to achieve ultra-sensitive detection of exosomal miRNA.
J Nanobiotechnology. 2022 Aug 2;20(1):357. doi: 10.1186/s12951-022-01568-6.
10
Circulating microRNAs as Reliable Tumor Biomarkers: Opportunities and Challenges Facing Clinical Application.
J Pharmacol Exp Ther. 2023 Jan;384(1):35-51. doi: 10.1124/jpet.121.000896. Epub 2022 Jul 9.
本文引用的文献
1
Influence of plasma processing on recovery and analysis of circulating nucleic acids.
PLoS One. 2013 Oct 18;8(10):e77963. doi: 10.1371/journal.pone.0077963. eCollection 2013.
2
Plasma processing conditions substantially influence circulating microRNA biomarker levels.
PLoS One. 2013 Jun 7;8(6):e64795. doi: 10.1371/journal.pone.0064795. Print 2013.
3
MiRNA-199a-3p: A potential circulating diagnostic biomarker for early gastric cancer.
J Surg Oncol. 2013 Aug;108(2):89-92. doi: 10.1002/jso.23358. Epub 2013 Jun 3.
4
Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort.
Breast Cancer Res. 2013 May 24;15(3):R42. doi: 10.1186/bcr3428.
5
MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls.
Clin Cancer Res. 2013 Jul 1;19(13):3600-10. doi: 10.1158/1078-0432.CCR-12-3092. Epub 2013 May 22.
6
Identification and evaluation of plasma microRNAs for early detection of colorectal cancer.
PLoS One. 2013 May 14;8(5):e62880. doi: 10.1371/journal.pone.0062880. Print 2013.
7
microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers.
Oncol Rep. 2013 Jul;30(1):320-6. doi: 10.3892/or.2013.2475. Epub 2013 May 15.
8
miRNA-Seq normalization comparisons need improvement.
RNA. 2013 Jun;19(6):733-4. doi: 10.1261/rna.037895.112. Epub 2013 Apr 24.
9
Centrifugation: an important pre-analytic procedure that influences plasma microRNA quantification during blood processing.
Chin J Cancer. 2013 Dec;32(12):667-72. doi: 10.5732/cjc.012.10271. Epub 2013 Apr 19.
10
An Empirical Evaluation of Normalization Methods for MicroRNA Arrays in a Liposarcoma Study.
Cancer Inform. 2013 Mar 18;12:83-101. doi: 10.4137/CIN.S11384. Print 2013.
Zotero 插件